1446321-95-4

Usage

Uses

Used in Pharmaceutical Synthesis:
3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine hydrochloride is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications in treating a range of diseases and conditions.
Used in Agrochemical Development:
In the agrochemical industry, 3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine hydrochloride is utilized as a building block for the creation of novel agrochemicals. Its incorporation into these products can lead to the development of more effective and targeted pest control solutions, contributing to improved crop yields and food security.
Used in Medicinal Chemistry Research:
3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine hydrochloride serves as a valuable compound in medicinal chemistry research. Its unique structural features make it an attractive candidate for the design and synthesis of new drug molecules, potentially leading to the discovery of innovative treatments for various medical conditions.
Used in Drug Discovery:
In the field of drug discovery, 3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine hydrochloride is employed as a starting material for the development of new pharmaceutical agents. Its versatile chemical properties enable researchers to explore its potential in creating compounds with novel mechanisms of action, ultimately contributing to the advancement of medicine and healthcare.

Upstream product

• 109-09-1 2-chloropyridine 
• 2942-59-8 2-chloronicotinic acid 
• 1282518-60-8 1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 42330-59-6 (2-chloropyrid-3-yl)methanol 
• 1446321-93-2 [2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methanol 
• 1446321-92-1 (E)-1-(3-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-2-yl)-3-(dimethylamino)prop-2-en-1-one 
• 1446321-91-0 1-(3-((tert-butyldimethylsilyloxy)methyl)pyridin-2-yl)ethanone 
• 210037-84-6 3-{[(tert-butyldimethylsilyl)oxy]methyl}pyridine-2-carbonitrile 
• 524019-50-9 2-bromo-3-(((tert-butyldimethylsilyl)oxy)methyl)pyridine 
• 131747-54-1 (2-bromopyrid-3-yl)methanol 
• 35905-85-2 2-bromonicotinic acid 

Downstream Products

• 1446321-46-5 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde 
• 1446321-56-7 2-fluoro-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde 

Relevant academic research and scientific papers

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR

The invention relates to a process for the preparation of Voxelotor, or a salt or solvate thereof, which comprises the use of a compound of formula (I) or (I'), or a salt or solvate thereof.

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (36), that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. Unlike earlier allosteric activators that bind covalently to hemoglobin in a 2:1 stoichiometry, 36 binds with a 1:1 stoichiometry. Compound 36 is orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ～150. This partitioning onto the target protein is anticipated to allow therapeutic concentrations to be achieved in the red blood cell at low plasma concentrations. GBT440 (36) is in Phase 3 clinical trials for the treatment of sickle cell disease (NCT03036813).

1:1 adducts of sickle hemoglobin

Provide herein are 1:1 adducts of sickle hemoglobin (HbS) and a compound of formula (I), as defined herein, suitable as modulators of HbS, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

1:1 ADDUCTS OF SICKLE HEMOGLOBIN

Provide herein are 1:1 adducts of sickle hemoglobin (HbS) and a compound of formula (I), as defined herein, suitable as modulators of HbS, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

Compounds and uses thereof for the modulation of hemoglobin

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.